CHEMM.CO
CHEMM.CO
DK0060055861
ChemoMetec A/S
Loading chart...

Company Profile

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter NC-203, a high-precision cell counter designed to deliver complex cell samples; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; and XcytoMatic 40, a cell density and viability analyzer. In addition, the company provides consumables comprising cassettes, reagents, lysis, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans and training. Further, it develops XcytoMatic 30 cell counter and Xcyto 5. ChemoMetec A/S was incorporated in 1997 and is headquartered in Allerød, Denmark.

Related stocks

GN.CO
GN.CO • Denmark
GN Store Nord A/S
107.85 DKK
2.35B USD 1Y -12.4%
AMBU-B.CO
AMBU-B.CO • Denmark
Ambu A/S
72.85 DKK
2.85B USD 1Y -33.6%
ELN.MI
ELN.MI • Italy
EL.EN.
16.05 EUR
1.44B USD 1Y +34.9%
MED.SW
MED.SW • Switzerland
MEDARTIS N
82.4 CHF
1.24B USD 1Y -4%
VITR.ST
VITR.ST • Sweden
Vitrolife AB
95.6 SEK
1.3B USD 1Y -33.5%
EUZ.DE
EUZ.DE • Germany
Eckert & Ziegler SE I
12.36 EUR
866.7M USD 1Y -30.5%
NVCR
NVCR • Switzerland
NovoCure Limited
14.58 USD
1.7B USD 1Y -0.9%
EKTA-B.ST
EKTA-B.ST • Sweden
Elekta AB ser. B
54.45 SEK
2.08B USD 1Y +8%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
57.6% p.a.
Max Drawdown (5Y)
-77.7%
Sharpe Ratio (5Y)
-0.20
Beta Factor
1.37
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 50.6 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (57.6% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -79.0% in the extended horizon.
ende